| | |

High PD-L1 Levels Could Be Bad News for Mesothelioma Surgery Candidates

ByAlex Strauss
PD-L1 Levels

Yet another new study has found a link between PD-L1 levels and mesothelioma survival – this time in people slated to have surgery for malignant pleural mesothelioma. 

PD-L1 stands for programmed cell death ligand 1. It is a protein expressed by some cancer cells that helps them avoid immune system attack. 

Researchers at Baylor College of Medicine are the latest to show that higher PD-L1 levels may lead to a worse mesothelioma prognosis. Their study focused specifically on mesothelioma surgery candidates. 

The results were published recently in the Annals of Thoracic Surgery. 

PD-L1 Levels and Mesothelioma Prognosis

Even healthy people express some amount of PD-L1. Its job is to suppress the part of the immune system that attacks foreign tissues. It helps to protect a growing fetus, for instance. 

But in the case of mesothelioma, elevated PD-L1 levels are not good. The protein can keep cancer-killing immune system cells from doing their job. If the immune system cannot kill mesothelioma cells in the early stages, asbestos cancer can spread even faster. 

Researchers have only recently made the connection between PD-L1 levels and mesothelioma prognosis. The Baylor study takes it a step further. It applies doctors’ growing understanding of PD-L1 to mesothelioma surgery.

Planning for Mesothelioma Surgery

Many studies suggest that, if a person is healthy enough, mesothelioma surgery may give them the best odds of survival. If surgeons can remove all or most of the mesothelioma tumor, chemotherapy and/or radiation might be able to kill the remaining cells. 

But mesothelioma surgery is also hard on the body and carries many risks. Until recently, PD-L1 levels have not played into surgical decision-making for mesothelioma. 

But the Baylor study could change that. Researchers started with a meta-analysis of 14 studies including more than 1600 patients to confirm that high PD-L1 levels are linked to poor mesothelioma survival. 

Then they analyzed PD-L1 expression in 75 patients who had surgery for pleural mesothelioma. Sixty-five percent of the patients had PD-L1 levels above one percent. Patients with non-epithelioid subtypes tended to have the highest levels. 

“High tumor PD-L1 expression was independently associated with poor overall survival,” writes lead author Hyun-Sung Lee. “The association of PD-L1 overexpression with unfavorable survival was more significant in epithelial MPMs than non-epithelial MPMs.” 

Dr. Lee says almost a third of patients with non-epithelioid mesothelioma had tumors with over 50 percent PD-L1 expression. 

The researchers validated their findings in two other groups of patients. They concluded that patients and doctors should consider PD-L1 levels when making decisions about surgery. 

“Tumor PD-L1 expression is a prognostic biomarker in patients undergoing surgical resection for malignant pleural mesothelioma and may be useful in perioperative decision making,” they write. 

Source:

Lee, HS, et al, “Prognostic Role of Programmed Cell Death 1 Ligand 1 (PD-L1) in Resectable Pleural Mesothelioma”, November 26, 2020, Annals of Thoracic Surgery, Online ahead of print, https://linkinghub.elsevier.com/retrieve/pii/S0003497520320075

Similar Posts

  • | |

    Mesothelioma survivor Paul Kraus, alive and well 19 years after writing “Surviving Mesothelioma and Other Cancers

    ByAlex Strauss

    Paul Kraus is considered the longest documented mesothelioma survivor in the world. He was diagnosed in 1997 with mesothelioma so widespread that he was given little hope of survival. Not willing to give up, he worked with a team of doctors to create his own tailored treatment protocol. This protocol included dramatic life style change, experimental therapies, dietary changes, mind-body medicine, and other modalities. Paul was fortunate. The protocol he and his doctors created helped him keep the mesothelioma in check. His book “Surviving Mesothelioma and Other Cancers: A Patient’s Guide” details his cancer voyage, the decisions he made, and his philosophies about health and healing. This book is now the best-selling mesothelioma book in the world and has inspired…

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • |

    Mesothelioma Still Rising Despite Ban in Ireland

    ByAlex Strauss

    A study in Ireland confirms that it can take many years for a ban on asbestos to have a measurable impact on a country’s rates of malignant mesothelioma. Mesothelioma is the most serious of a list of diseases – including lung cancer, pleural plaques, asbestosis, and others – linked with exposure to asbestos dust. Affecting the linings around the lungs and other organs, mesothelioma is often resistant to most cancer treatments and may be fatal within a year of diagnosis. According to the International Ban Asbestos Secretariat, Ireland is one of 55 countries that have enacted some type of asbestos ban. However, although Ireland banned asbestos in 2000, a new study published in Cancer Epidemiology shows that incidence of the…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Website Aims to Protect Homeowners from Mesothelioma

    ByAlex Strauss

    Australia’s Cancer Council is trying to educate home renovators about their risk for mesothelioma with a new e-learning course. Australia has one of the highest per capita rates of mesothelioma in the world, largely because of several asbestos mining operations that were once located there. Although asbestos has been banned from building products in Australia since 1989, asbestos-linked diseases like mesothelioma, lung cancer, and asbestosis continue to pose a serious health concern. While mesothelioma has traditionally occurred among people exposed to asbestos on the job, Australia is now bracing for another “wave” of mesothelioma victims among homeowners who encounter asbestos while doing their own renovation projects. Cancer Council Australia has launched “kNOw asbestos in your home” in an effort to…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    ByAlex Strauss

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…